Age-related macular degeneration, anti-VEGF therapy, and ophthalmic imaging: is there a best practice?

JAMA Ophthalmol. 2013 Sep;131(9):1124-6. doi: 10.1001/jamaophthalmol.2013.432.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Angiogenesis Inhibitors / economics
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / economics
  • Bevacizumab
  • Drug Costs
  • Humans
  • Practice Guidelines as Topic*
  • Ranibizumab
  • Tomography, Optical Coherence*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Wet Macular Degeneration / diagnosis*
  • Wet Macular Degeneration / drug therapy*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Ranibizumab